Central diabetes insipidus in children: Diagnosis and management.
Adolescent
Age of Onset
Biomarkers
/ analysis
Brain
/ diagnostic imaging
Child
Diabetes Insipidus, Neurogenic
/ diagnosis
Diagnosis, Differential
Diagnostic Imaging
/ methods
Diagnostic Techniques, Endocrine
/ trends
Histiocytosis, Langerhans-Cell
/ complications
Humans
Magnetic Resonance Imaging
Polydipsia
/ diagnosis
Polyuria
/ diagnosis
DDAVP
Langerhans cell histiocytosis
MRI
diabetes insipidus
germ cell tumors
posterior pituitary
Journal
Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
11
7
2020
medline:
16
3
2021
entrez:
11
7
2020
Statut:
ppublish
Résumé
Central diabetes insipidus (CDI) is a complex disorder in which large volumes of dilute urine are excreted due to arginine-vasopressin deficiency, and it is caused by a variety of conditions (genetic, congenital, inflammatory, neoplastic, traumatic) that arise mainly from the hypothalamus. The differential diagnosis between diseases presenting with polyuria and polydipsia is challenging and requires a detailed medical history, physical examination, biochemical approach, imaging studies and, in some cases, histological confirmation. Magnetic resonance imaging is the gold standard method for evaluating the sellar-suprasellar region in CDI. Pituitary stalk size at presentation is variable and can change over time, depending on the underlying condition, and other brain areas or other organs - in specific diseases - may become involved during follow up. An early diagnosis and treatment are preferable in order to avoid central nervous system damage and the risk of dissemination of germ cell tumor, or progression of Langerhans Cell Histiocytosis, and in order to start treatment of additional pituitary defects without further delay. This review focuses on current diagnostic work-up and on the role of neuroimaging in the differential diagnosis of CDI in children and adolescents. It provides an update on the best approach for diagnosis - including novel biochemical markers such as copeptin - treatment and follow up of children and adolescents with CDI; it also describes the best approach to challenging situations such as post-surgical patients, adipsic patients, patients undergoing chemotherapy and/or in critical care.
Identifiants
pubmed: 32646670
pii: S1521-690X(20)30067-1
doi: 10.1016/j.beem.2020.101440
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101440Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.